KBI Biopharma Executive and Leadership Team

Shardene Basisa, the Chief Executive Officer at KBI Biopharma, directs the company's overarching strategy and vision. This leadership role involves guiding KBI Biopharma's mission to drive breakthroughs in biopharmaceutical development and manufacturing, ensuring positive impacts on patient lives worldwide. Basisa oversees the integration of all departmental functions to achieve synergistic growth and operational excellence. The Chief Executive Officer's responsibilities include fostering a culture of innovation and accountability across the organization, setting ambitious goals for market expansion, and ensuring alignment with the company's commitment to being a next-generation CDMO. Shardene Basisa's strategic direction is crucial for navigating the complex biopharmaceutical landscape and solidifying KBI Biopharma's position as an industry leader. This executive ensures the company's operations consistently meet the highest standards of quality and regulatory compliance, driving forward the development of life-changing therapies.

Katherine Wolf, the Chief Financial Officer at KBI Biopharma, oversees all financial planning, reporting, and strategic fiscal management for the organization. Wolf's responsibilities encompass budgeting, forecasting, capital allocation, and investor relations, ensuring the financial health and sustainability of KBI Biopharma's operations. This executive guides the company's financial strategy to support its growth objectives and its mission of driving biopharmaceutical breakthroughs. The Chief Financial Officer plays a critical part in evaluating investment opportunities, managing financial risks, and optimizing the company's capital structure. Katherine Wolf's expertise is vital for maintaining financial discipline and transparency, enabling KBI Biopharma to continue its expansion as a leading CDMO. By managing financial resources effectively, Wolf directly supports the company's ability to invest in cutting-edge technologies and expand its global reach.

Peter Carbone, the Chief Operating Officer at KBI Biopharma, manages the day-to-day operational execution and efficiency across all manufacturing and development processes. Carbone's focus is on optimizing production workflows, enhancing supply chain logistics, and ensuring the seamless delivery of biopharmaceutical products to clients. This role involves direct oversight of manufacturing sites, quality control, and process development to meet stringent industry standards. The Chief Operating Officer drives initiatives aimed at scaling operations, improving resource allocation, and maintaining the highest levels of operational integrity. Peter Carbone's leadership ensures that KBI Biopharma's CDMO services are delivered with precision and reliability, supporting the company's commitment to advancing patient care through biopharmaceutical innovation. By streamlining operations, Carbone directly contributes to KBI Biopharma's capacity to accelerate drug development timelines and bring critical therapies to market faster.

Toshihiro Ogawa, the President, Kbi Biopharma (Japan) at KBI Biopharma, directs the company's strategic operations and market presence within Japan. Ogawa's leadership is focused on expanding KBI Biopharma's footprint in the Japanese biopharmaceutical sector, ensuring localized service delivery and client engagement. This role involves overseeing regional business development, regulatory compliance, and operational management specific to the Japanese market. The President, Kbi Biopharma (Japan) acts as the primary liaison for KBI Biopharma's activities in the region, driving growth and reinforcing the company's commitment to advancing patient care through biopharmaceutical development. Toshihiro Ogawa's expertise in the Japanese market is critical for adapting KBI Biopharma's CDMO services to meet local demands and regulatory requirements. By leading the Japanese division, Ogawa directly contributes to KBI Biopharma's global mission and its impact on patient lives.

Shaguna Seth, the Global Project Management Office Head Chief of Staff at KBI Biopharma, orchestrates the strategic execution of key projects and initiatives across the organization. Seth's role involves ensuring alignment between project goals and KBI Biopharma's broader strategic objectives, facilitating cross-functional collaboration, and driving operational efficiency. This leadership position requires meticulous planning, resource coordination, and risk management to ensure successful project completion. The Global Project Management Office Head Chief of Staff acts as a central point for project oversight, reporting on progress, and implementing best practices in project management. Shaguna Seth's contributions are essential for translating KBI Biopharma's vision into tangible outcomes, supporting the company's mission to advance biopharmaceutical development and manufacturing. By optimizing project delivery, Seth directly enhances KBI Biopharma's capacity to serve clients and impact patient lives.

Debra Bruneau, the Chief People Officer at KBI Biopharma, leads the human resources strategy, focusing on talent acquisition, development, and fostering a positive organizational culture. Bruneau's mandate includes building a high-performing workforce that supports KBI Biopharma's mission of driving biopharmaceutical innovation and manufacturing excellence. This executive oversees employee engagement, compensation and benefits, and organizational development initiatives designed to attract and retain top talent. The Chief People Officer plays a crucial role in ensuring that KBI Biopharma's workforce is equipped with the skills and motivation necessary to achieve the company's ambitious goals. Debra Bruneau's leadership in people management is fundamental to sustaining KBI Biopharma's growth and its commitment to positively impacting patient lives through advanced CDMO services. By cultivating a strong employee base, Bruneau directly strengthens the company's operational capabilities.